NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)
University of Pennsylvania researchers seek patients with one of the following types of cancers that test positive for NY-ESO-1 antigen:
- Multiple Myeloma
- Synovial Sarcoma
- Myxoid/Round Cell Liposarcoma
These patients may be eligible for an autologous (to the self) immune T-cell transplant after the immune cells have been gene modified to attack NY-ESO-1-positive tumor cells. The treatment will require leukapheresis to collect the T-cells for gene modification, which will take place in the lab and impart genes to target the cancer while removing genes that may cause an autoimmune response. Chemotherapy is required before they are re-infused. Follow up, including lab and imaging assessments, may continue for up to 5 years.
- Be 18 years of age or older
- Have confirmed diagnosis of relapsed refractory multiple myeloma (MM), melanoma, synovial sarcoma, or myxoid/round cell liposarcoma (MRCL) meeting past treatment criteria
- Be HIV negative
THE STUDY INVOLVES:
- Screening to confirm acceptance to the study.
- Leukapheresis to collect the patient’s own stem cells, which will be gene-modified in the lab (no treatment during that period) to target cancer cells.
- Admission to the study center and a course of chemotherapy.
- Infusion of the gene-modified stem cells.
- Follow up, including lab and imaging assessments, may continue for up to 5 years.
LOCATIONS & CONTACTS:
Trials will take place at the University of Pennsylvania in Philadelphia, PA. Map.
EmergingMed | 855-216-0098 | [email protected]
University of Pennsylvania
Parker Institute for Cancer Immunotherapy
Tmunity Therapeutics Inc.
Or go online: